Park Capital Management LLC WI Acquires New Shares in Johnson & Johnson (NYSE:JNJ)

Park Capital Management LLC WI bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,240 shares of the company's stock, valued at approximately $902,000. Johnson & Johnson accounts for about 1.1% of Park Capital Management LLC WI's investment portfolio, making the stock its 18th biggest holding.

Several other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp boosted its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. State Street Corp now owns 134,245,811 shares of the company's stock valued at $21,755,874,000 after buying an additional 1,154,088 shares during the period. Geode Capital Management LLC boosted its stake in Johnson & Johnson by 1.8% in the third quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company's stock valued at $9,064,149,000 after acquiring an additional 1,004,763 shares during the period. FMR LLC grew its holdings in shares of Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company's stock valued at $2,968,440,000 after purchasing an additional 1,265,748 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after purchasing an additional 102,502 shares during the period. Finally, Franklin Resources Inc. boosted its position in Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after purchasing an additional 1,729,281 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Johnson & Johnson Price Performance

Shares of JNJ traded up $2.94 during mid-day trading on Wednesday, hitting $157.93. The company's stock had a trading volume of 7,830,622 shares, compared to its average volume of 9,018,342. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The firm has a 50-day moving average price of $148.12 and a 200 day moving average price of $155.85. The stock has a market capitalization of $380.23 billion, a price-to-earnings ratio of 23.75, a PEG ratio of 2.50 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. Johnson & Johnson's revenue was up 5.3% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.14%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's payout ratio is 74.59%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Bank of America dropped their target price on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, January 23rd. Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Guggenheim lifted their price target on Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. Finally, Wells Fargo & Company cut their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.